Fujioka T, Hasegawa M, Ogiu K, Matsushita Y, Sato M, Kubo T
Department of Urology, Iwate Medical University School of Medicine, Japan.
J Urol. 1996 May;155(5):1775-8.
The effect of 0-(chloroacetyl-carbamoyl) fumagillol (TNP-470) on tumor growth and metastasis is investigated.
BALB/c mice were inoculated with Renca murine tumor and graded doses of TNP-470 were given subcutaneously every other day beginning on day 1 and ending on day 9. Tumor angiogenesis was measured quantitatively by a colorimetric assay.
TNP-470 inhibited tumor growth and prolonged the life span of Renca-bearing mice in a dose-dependent manner. Body weight-loss was not observed in the mice given less than 30 mg./kg./day. When the treatment was delayed on day 6, TNP-470 did not inhibit tumor growth, pointing to the importance of the timing of drug administration in relation to disease stage. Tumor angiogenesis was inhibited 33 to 62% of the control level by TNP-470. Furthermore, TNP-470 reduced pulmonary and hepatic metastatic foci of intravenously inoculated Renca and of the tumor inoculated in the spleen.
These data suggest that TNP-470 may be effective as a treatment of renal cell carcinoma, especially when micrometastases are involved.
研究0-(氯乙酰-氨甲酰基)烟曲霉素(TNP-470)对肿瘤生长和转移的影响。
给BALB/c小鼠接种Renca鼠肿瘤,从第1天开始至第9天,每隔一天皮下给予不同剂量的TNP-470。通过比色法对肿瘤血管生成进行定量测量。
TNP-470以剂量依赖的方式抑制肿瘤生长并延长荷Renca小鼠的寿命。给予剂量小于30mg/kg/天的小鼠未观察到体重减轻。当在第6天延迟治疗时,TNP-470未抑制肿瘤生长,这表明给药时间与疾病阶段相关的重要性。TNP-470将肿瘤血管生成抑制至对照水平的33%至62%。此外,TNP-470减少了静脉接种Renca以及脾脏接种肿瘤后的肺和肝转移灶。
这些数据表明TNP-470可能作为治疗肾细胞癌的有效药物,尤其是在存在微转移的情况下。